Teladoc Health, INC Form 4 insider transactions

Daniel Trencher, Chief Strategy Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities.

Teladoc Health's Chief Operating Officer, Michael Willem Waters, reports the sale of shares to cover tax obligations related to vesting performance stock units and restricted stock units.

EVP Andrew Turitz reports the acquisition and disposal of Teladoc Health (TDOC) common stock and derivative securities, including transactions related to vesting of performance and restricted stock units.

Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, reports the vesting and subsequent sale of shares to cover tax obligations.

Director Mark Douglas Smith recently purchased 4,000 shares of Teladoc Health (TDOC) at $7.078 per share, increasing his holdings to 8,355 shares.

Chief Technology Officer Nikolaos P. Nanis of Teladoc Health, Inc. reports the acquisition and disposal of company stock and restricted stock units.

Stephany Verstraete, Chief Marketing Officer of Teladoc Health, sold 15,000 shares of common stock on August 7, 2024, at a price of $7.6 per share.

Director Thomas McKinley recently acquired 11,000 shares of Teladoc Health (TDOC) common stock through open market purchases.

Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, sold 1,537 shares of common stock on August 5, 2024, at a price of $7.33 per share.

Teladoc Health's Chief Operating Officer, Michael Willem Waters, reported the acquisition and disposal of company stock, including the sale of shares to cover tax obligations related to vesting restricted stock units.

Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, reports the acquisition and disposal of company stock and restricted stock units.

Laizer Kornwasser, an Advisor to the CEO at Teladoc Health, reported the acquisition and disposal of common stock and restricted stock units.

Nikolaos P. Nanis, Chief Technology Officer of Teladoc Health, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Teladoc Health's CEO, Charles Divita III, reports the acquisition of 469,924 restricted stock units (RSUs) on June 10, 2024, according to a Form 4 filing with the SEC.

Mala Murthy, Acting CEO and CFO of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities.

Arnnon Geshuri, Chief People Officer of Teladoc Health, reports the acquisition and disposal of Teladoc Health common stock and derivative securities.

EVP Andrew Turitz of Teladoc Health reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units.

Michael Willem Waters, Chief Operating Officer of Teladoc Health, reports the acquisition and disposal of company stock and derivative securities.

Laizer Kornwasser, President of Enterprise Growth at Teladoc Health, reports the acquisition and disposal of company stock and derivative securities.

Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, reports transactions involving common stock, performance stock units, and restricted stock units.

Daniel Trencher, Chief Strategy Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities related to performance stock units and restricted stock units.

Chief Marketing Officer of Teladoc Health, Stephany Verstraete, reports acquisition and disposal of company stock and derivative securities.

James L. Cave, Interim CAO of Teladoc Health, reports the acquisition and disposal of common stock and restricted stock units.

Nikolaos P. Nanis, Chief Technology Officer of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities related to performance stock units and restricted stock units.

Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities.

Director David L. Shedlarz reports acquisition of 17,467 restricted stock units and conversion of 9,834 restricted stock units into common stock.

Director Kenneth Paulus acquired 17,467 restricted stock units in Teladoc Health, Inc. on May 23, 2024, which will vest on the earlier of May 23, 2025, or the day before the 2025 annual meeting of stockholders.

Director David B. Snow Jr. reports acquisition of shares through restricted stock unit conversion and grant.

Director Jason Eric Evans reports acquisition of 17,467 restricted stock units in Teladoc Health, Inc.

Sandra L. Fenwick, a director of Teladoc Health, Inc., acquired 17,467 restricted stock units on May 23, 2024, which will vest on the earlier of May 23, 2025, or the day before the 2025 annual meeting of stockholders.